Business
Futura Medical plc Board Appointment
Futura Medical plc Board Appointment.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4981Q\n Futura Medical PLC\n 28 October 2021\n \n \n \n \n 28 October 2021\n \n \n \n \n \n \n Futura Medical plc\n \n \n \n (\"Futura\" or the \"Company\")\n \n \n Board Appointment\n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce that Andrew Unitt is being appointed to the Board as a non-executive director with effect from 1 January 2022. Andrew will replace Jonathan Freeman who will be stepping down as senior independent non-executive director on the 31 of December 2021.\n \n \n Andrew spent eleven years at Boots plc, where he was Finance Director for four years of Boots Healthcare International, its over-the-counter medicines business. Andrew is currently a non-executive director of AIM company, Oncimmune Holdings Plc and was previously Chief Financial Officer at the University of Nottingham until July 2016. Prior to working in higher education, Andrew was a Finance Director for 20 years in a wide range of industries. Andrew has also held several non-executive directorships within the NHS and private sector.\n \n \n \n Commenting on the appointment, James Barder, Chief Executive Officer of the Company, said: \"\n \n Andrew is a welcome addition to the Futura Medical Board at this particular stage of the Company. His strong financial experience, OTC market expertise and exceptional skills in strategic development and business management will further enhance our ambition and focus as we execute commercialisation of MED3000 as a global brand, strengthen our distribution network and continue to accelerate Company growth towards long term, sustainable revenues. On behalf of the Board, I would like to thank Jonathan for his long standing commitment and support to Futura over the years. His contribution is very much appreciated, and I wish him all the best in his future commitments.\"\n \n \n MED3000 is a topically applied gel which utilises our proprietary DermaSys® technology, developed specifically for treatment of ED. MED3000 has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market as well as being available without a d...